Mechanism of Wulingsan in Treatment of Rheumatoid Arthritis Based on Network Pharmacology
10.13422/j.cnki.syfjx.20191802
- VernacularTitle: 基于网络药理学探讨五苓散治疗类风湿关节炎的作用机制
- Author:
Kai QIAN
1
;
Yan-yi DU
1
;
Long-yin HAN
1
;
Zhen-quan WEI
1
;
Wen-guang HUANG
1
;
Li-ying ZENG
1
;
Shu-di XU
1
;
Min-ying LIU
2
;
Chang-song LIN
2
Author Information
1. Guangzhou University of Chinese Medicine, Guangzhou 510405, China
2. The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China
- Publication Type:Research Article
- Keywords:
Wulingsan;
network pharmacology;
rheumatoid arthritis;
target;
signaling pathway
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(19):138-146
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the mechanism of Wulingsan (WLS) in the treatment of rheumatoid arthritis (RA) by network pharmacology. Method:The active components of WLS were screened on traditional Chinese medicine systems pharmacology(TCMSP) platform, and the targets were predicted in DragBank database. The "component-target" network was constructed by Cytoscape 3.2.1 software. Disease targets were searched in TTD, DrugBank and DisGenet databases. The Venn diagram was built to extract the target of WLS in the treatment of RA, and the gene oesthetics(GO) function annotation and Kyoto Encyclopedin of Genes and Genomes(KEGG) signal pathway enrichment analysis were performed by cluego plugin. The TCM-component-target-pathway network of WLS was constructed, and the network feature analysis was made by Network Analyzer. Result:Totally 52 components and 297 potential targets in WLS and 1 845 targets relating to RA were excavated, and 49 common targets of WLS-RA were obtained. The common targets were mainly enriched in 322 biological processes and 31 signaling pathways. Conclusion:WLS may regulate targets, such as prostaglandin epoxide synthase 2 (PTGS2), transforming growth factor-β1 (TGF-β1), cysteine aspartate protein-3 (Caspase-3), transcription factor p65 (RELA), progesterone receptor (PGR), and adjust cancer-related pathways, tumor necrosis factor(TNF) signaling pathways, interleukin-17(IL-17) signaling pathways, nuclear factor-κB(NF-κB) signaling pathways, Th17 cell differentiation, so as to inhibit the inflammatory response, regulate immune function and adjust apoptosis to treat rheumatoid arthritis.
